Association Between High Gal-3 Serum Levels and Worsening of Renal Function in Chronic Heart Failure Outpatients

Iacoviello, Massimo; Serio, Francesca Di; Rizzo, Caterina; Leone, Marta; Grande, Dario; Guida, Pietro; Gioia, Michele De; Parisi, G.; Leopizzi, Tiziana; Caldarola, Pasquale; Ciccone, Marco Matteo; Gesualdo, Loreto

doi:10.2217/bmm-2018-0349

Cited by 18 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 This is a secondary analysis of a prospective study; main results have already been published. 12 The retrospective analysis relative to the present study was approved by the ethics committee of Policlinic University Hospital of Bari, Italy. Informed consent was obtained from all participants in the study.…”

Section: Methods Patientsmentioning

confidence: 99%

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aims Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to have a relevant role in the prevention of hospitalizations for heart failure and improvement in the life expectancy of patients with diabetes and outpatients with chronic heart failure (CHF) with reduced left ventricular ejection fraction, independently from the presence of type 2 diabetes mellitus (T2DM). The aim of our study was to evaluate in a real-world population the number of outpatients with CHF who meet the enrolment criteria of the main randomized controlled trials (RCT) published in the last 5 years and consequently identify the percentage of patients who could potential benefit from SGLT2i therapy. Methods and resultsWe retrospectively evaluated all consecutive outpatients referred for CHF. The diagnosis of T2DM was according to the latest European Society of Cardiology Guidelines. Clinical characteristics considered for the enrolment in the RCTs were recorded. We enrolled 515 patients, 384 (75%) of whom had a left ventricular ejection fraction (LVEF) ≤ 40%, 82 (16%) had pre-diabetes, and 187 (36%) had diabetes. Most of the patients with LVEF ≤ 40% met the criteria for the DAPA-HF trial (65%), and this percentage was even higher if the serum level of N-terminal pro-brain natriuretic peptide was not considered. A high percentage of patients with diabetes and LVEF > 40% met the criteria for the DECLARE (39%), CANVAS (47%), and EMPA-REG (30%) trials. Patients meeting the enrolment criteria of RCTs evaluating SGLT2i were also characterized by a high risk of heart failure events during follow-up. Conclusions In spite of a low number of patients actually treated with SGLT2i, we observed that a high prevalence of patients with CHF met the clinical characteristics of RCTs that have demonstrated a beneficial effect of SGLT2i.

show abstract

Section: Methods Patientsmentioning

confidence: 99%

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…e galectin-3 (Gal-3) is a member of the galectin family and plays a key role in the diagnosis of myocardial infarction, heart failure, and other diseases [10]. Martínez-Martínez's et al [11] believed that myocardial fibrosis is the main factor leading to heart failure.…”

Section: Introductionmentioning

confidence: 99%

Levels of Serum sST2, MMP-3, and Gal-3 in Patients with Essential Hypertension and Their Correlation with Left Ventricular Hypertrophy

Wang

Han

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Essential hypertension (EH) is a clinically frequent cardiovascular disease, with insidious onset, causing increased pressure load and neuroregulation disorders in patients. Long-term EH can cause left ventricular hypertrophy (LVH), which can lead to arrhythmia and even death. The soluble suppression of tumorigenicity 2 (sST2), matrix metalloproteinase-3 (MMP-3), and galectin-3 (Gal-3) in serum plays an important role in the occurrence, development, and prognosis of cardiovascular diseases. In our study, we divided EH patients into 3 levels and groups with or without LVH, according to their condition. The levels of sST2, MMP-3, and Gal-3 in the serum were measured in different groups of patients. Our results showed that the levels of sST2, MMP-3, and Gal-3 in the serum increased progressively with the level in different EH groups. The levels of sST2, MMP-3, and Gal-3 in the serum of the LVH group were higher than those of the NLVH group, and it is positively correlated with LVH-related indexes. The risk of developing and progressing to LVH in patients with EH can be determined by the method of measuring three indicators.

show abstract

“…In humans, Gal-3 levels are correlated with GFR, but higher Gal-3 plasma galectin-3 levels are also associated with a greater risk of developing incident CKD [53,54]. Analogously, in CHF patients, higher Gal-3 serum levels are not only strongly associated with lower GFR [55] and microalbuminuria [43], but also with an increased risk renal function worsening [44]. Patients with high Gal-3 showed a steeper decline of GFR during a three year follow-up and this was even more evident in patients with apparently preserved renal function, thus strengthening the possible role of this biomarker in early detection of renal dysfunction.…”

Section: Renal Biomarkers In Chronic Kidney and Cardiovascular Diseasesmentioning

confidence: 99%

“…Galectin-3. Aside from microalbuminuria, Galectin-3 (Gal-3) could represent a biomarker able to give information about the pathophysiological background underlying renal dysfunction and its progression in patients with CVD [43][44][45]. Gal-3 is a beta galactoside binding lectin, expressed in various tissues and cell types and detectable inside and outside cells [46,47].…”

Section: Renal Biomarkers In Chronic Kidney and Cardiovascular Diseasesmentioning

confidence: 99%

“…Moreover, an approach based on the evaluation of BNP and bio impedance analysis has been proposed in order to better tailor diuretic therapy and reduce the occurrence of AKI [101]. In chronic HF, NT-proBNP is associated with WRF, but this association is not independent from the other clinical and echocardiographic parameters and Galectin -3 [44].…”

Section: Cardiac Biomarkers In Kidney Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in Cardiorenal Syndrome

Goffredo

Barone

Terlizzi

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

Cardiorenal syndrome is a clinical manifestation of the bidirectional interaction between the heart and kidney diseases. Over the last years, in patients with cardiovascular diseases, several biomarkers have been studied in order to better assess renal function as well as to identify patients prone to experiencing chronic or acute worsening of renal function. The aim of this review is to focus on the possible clinical usefulness of the most recent biomarkers in the setting of cardiorenal syndrome.

show abstract

Association Between High Gal-3 Serum Levels and Worsening of Renal Function in Chronic Heart Failure Outpatients

Cited by 18 publications

References 22 publications

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors

Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors

Levels of Serum sST2, MMP-3, and Gal-3 in Patients with Essential Hypertension and Their Correlation with Left Ventricular Hypertrophy

Biomarkers in Cardiorenal Syndrome

Contact Info

Product

Resources

About